Anxiety disorders affect women at approximately twice the rate of men. Generalized anxiety disorder, panic disorder, and social anxiety all show consistent female predominance across cultures and age groups. Yet most anxiolytic research is conducted predominantly in male subjects, and most pharmaceutical options were developed without sex-specific considerations.
Selank is a synthetic heptapeptide with anxiolytic and nootropic properties that has been approved in Russia for anxiety and neurasthenia since 2009. It represents a mechanistically distinct approach to anxiety that operates through peptide-based modulation of GABA, serotonin, and BDNF rather than through the serotonin reuptake inhibition used by most Western-market anxiolytics.
Why Anxiety Is a Women's Health Issue
The sex difference in anxiety is not purely cultural. Biological factors include estrogen and progesterone fluctuations across the menstrual cycle (progesterone metabolites interact with GABA receptors), differences in amygdala reactivity and connectivity, and differences in HPA axis stress response. Anxiety often worsens during periods of hormonal transition: premenstrually, postpartum, and during perimenopause.
Women also metabolize many anxiolytic medications differently. SSRIs, the most commonly prescribed anxiolytics, show sex-dependent pharmacokinetics: women achieve higher blood levels at the same dose, experience more side effects (including sexual dysfunction, weight gain, and emotional blunting), and have different optimal dosing than men.
What Selank Is and How It Works
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of tuftsin, an immunomodulatory peptide. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied for anxiolytic, nootropic, and immunomodulatory effects.
Its mechanisms include enhancing GABAergic signaling (GABA is the primary inhibitory neurotransmitter and the target of benzodiazepines), modulating serotonin metabolism (increasing serotonin availability through enzyme inhibition rather than reuptake blockade), increasing BDNF (brain-derived neurotrophic factor) expression which supports neuroplasticity and stress resilience, and reducing inflammatory cytokines in the brain.
Selank is administered intranasally, which provides rapid CNS access through the olfactory pathway. This bypasses the blood-brain barrier and reduces systemic side effects compared to oral medications.
The Evidence Base
Selank has been studied in several Russian clinical trials for generalized anxiety disorder. Studies report significant reductions in anxiety scores (Hamilton Anxiety Rating Scale) compared to placebo, with onset of anxiolytic effects within days rather than the 4 to 6 weeks typically required for SSRIs. Side effect profiles in these trials were favorable, with no reported sedation, cognitive impairment, or dependence.
Important caveats: these trials were conducted primarily in Russian research institutions, have not been replicated in Western clinical trials, and are published in journals with varying peer-review rigor. The evidence is promising but not at the level of Western regulatory standards. Selank is not FDA-approved for any indication.
Selank vs SSRIs: Different Mechanisms
SSRIs work by blocking serotonin reuptake, increasing serotonin availability in the synaptic cleft. This is effective for many patients but produces side effects including sexual dysfunction (affecting 40 to 70 percent of users), weight gain, emotional blunting, and discontinuation syndrome. SSRIs also take 4 to 6 weeks to reach full effect and can paradoxically worsen anxiety during the initiation phase.
Selank modulates the same neurotransmitter systems through different mechanisms. It enhances GABA without the sedation and dependence risk of benzodiazepines. It increases serotonin through enzyme modulation rather than reuptake blockade, which may explain the different side effect profile. And it increases BDNF, providing a neuroplasticity component that SSRIs achieve only secondarily.
These are not equivalent treatments with equivalent evidence. SSRIs have decades of rigorous Western clinical trial data. Selank has promising but limited evidence by Western standards. The mechanistic comparison is relevant for understanding alternatives, not for replacing proven treatments without clinical guidance.
The Perimenopause Angle
Anxiety frequently worsens during perimenopause as estrogen fluctuations destabilize serotonin and GABA signaling. Progesterone, which has natural anxiolytic effects through its metabolite allopregnanolone acting on GABA-A receptors, also becomes erratic.
For perimenopausal women who develop new-onset anxiety or experience worsening of existing anxiety, Selank's GABAergic mechanism may be particularly relevant because it supports the same inhibitory pathway that progesterone's metabolites naturally enhance. As progesterone becomes unreliable, an exogenous GABA modulator may help fill the gap.
PMOS and Anxiety
Women with PMOS have significantly higher rates of anxiety and depression than age-matched controls, even after controlling for BMI and visible symptoms. The mechanisms likely involve insulin resistance effects on brain neurotransmitter function, chronic inflammation affecting neuroinflammatory pathways, and the psychological burden of managing a chronic, often-dismissed condition.
Selank's combination of anxiolytic and anti-inflammatory properties makes it theoretically relevant for the PMOS population, where anxiety may be driven by both neurochemical and inflammatory mechanisms.
Practical Considerations
Selank is available as a research peptide, typically in intranasal formulations. Standard research protocols use 200 to 400 mcg intranasally, 1 to 3 times daily. Effects are typically noticeable within the first few days, which is dramatically faster than SSRI onset.
Selank does not appear to cause dependence or withdrawal effects in the available literature, distinguishing it from benzodiazepines. However, long-term safety data is limited, and anyone using Selank should do so under the guidance of a healthcare provider familiar with peptide therapy.
If you are currently on an SSRI or other psychiatric medication, do not stop or modify your medication to try Selank. Any changes to psychiatric treatment should be made in collaboration with your prescribing provider.
Take the quiz to see if Selank matches your mood and wellness goals.
Peptide Quiz →